Results 221 to 228 of about 23,901 (228)

Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?

European Journal of Cancer, 2017
Emanuela Palmerini, S P Chawla, S P Chawla   +2 more
exaly  

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies

Osteoporosis International, 2018
David Kendler, Henry Bone, Maria Luisa Brandi   +2 more
exaly  

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension†‡

Journal of Bone and Mineral Research, 2012
Jean-Yves Reginster, Roland Chapurlat, Steven R Cummings   +2 more
exaly  

Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX

Journal of Bone and Mineral Research, 2012
John Kanis, Helena Johansson, Eugene V McCloskey   +2 more
exaly  

Denosumab

Reactions Weekly, 2012
openaire   +1 more source

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

Osteoporosis International, 2011
Jacques P. Brown, J F Modlin, A Grauer
exaly  

Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors

Breast Cancer Research and Treatment, 2019
Elena Gonzalez-Rodriguez, Khalil Zaman, Bérengère Aubry-Rozier   +2 more
exaly  

Denosumab and osteonecrosis of the jaws – the pharmacology, pathogenesis and a report of two cases

Australian Dental Journal, 2014
exaly